Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
257 hedge funds and large institutions have $4.92B invested in Akero Therapeutics in 2025 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 87 increasing their positions, 87 reducing their positions, and 39 closing their positions.
107% more call options, than puts
Call options by funds: $100M | Put options by funds: $48.2M
46% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 39
40% more capital invested
Capital invested by funds: $3.5B → $4.92B (+$1.41B)
23% more funds holding in top 10
Funds holding in top 10: 13 → 16 (+3)
7% more funds holding
Funds holding: 240 → 257 (+17)
7.02% more ownership
Funds ownership: 108.56% → 115.58% (+7%)
0% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 87
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$159M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$100M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$90.3M |
| 4 |
Holocene Advisors
New York
|
+$48.9M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$48.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$115M |
| 2 |
RI
RTW Investments
New York
|
-$88.2M |
| 3 |
SG Americas Securities
New York
|
-$52.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$33.6M |
| 5 |
BlackRock
New York
|
-$21.6M |
AKRO Hedge Fund Activity: Q2 2025 in Review
257 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q2 2025, worth a combined $4.92B — up 40% from $3.5B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new AKRO positions and 39 closed out — a net gain of 18 holders — while 87 added to existing stakes and 87 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $159M. The largest seller was Wellington Management Group, cutting an estimated $115M.
- 257 institutional investors held Akero Therapeutics (AKRO) as of Q2 2025, up from 240 in Q1 2025.
- Funds reported $4.92B of Akero Therapeutics stock for Q2 2025, up 40% quarter-over-quarter.
- 57 funds opened new Akero Therapeutics positions in Q2 2025 and 39 closed out, a net change of +18 holders.
- The largest Akero Therapeutics buyer in Q2 2025 was Avoro Capital Advisors, an estimated $159M added.
- The largest Akero Therapeutics seller in Q2 2025 was Wellington Management Group, an estimated $115M sold.
Based on aggregated 13F filings for Q2 2025.